Home·Stocks·VCYT
Veracyte, Inc.

VCYT

XNAS

Veracyte, Inc.

Healthcare · Services-Medical Laboratories

$46.44
-1.65 (-3.44%)
15-min delayed

Drag to pan · Scroll to zoom · Hover for OHLC

Snapshot
Loading metrics…
About Veracyte, Inc.

Veracyte Inc is a genomic diagnostics company. The group empowers clinicians with the insights necessary to guide and assure patients at pivotal moments in the race to diagnose and treat cancer. It offers tests for prostate cancer (Decipher Prostate), thyroid cancer (Afirma), breast cancer (Prosigna), and bladder cancer (Decipher Bladder).

Employees
755
Country
US
IPO Date
2013-10-30
www.veracyte.com →
Recent News
Needham Reiterates Buy on Veracyte, Maintains $48 Price Target
Benzinga · 2d ago
Veracyte: The Evidence Flywheel Is Turning Into A Cash Flow Platform
SeekingAlpha · 2d ago
COMMUNITY · $VCYT0 theses
POST YOUR TAKE →
Analyst Ratings
Loading…
Financials
Loading SEC filings…
Insider Activity
Loading filings…
Related Stocks
Loading peers…
Ask AI about VCYTBuild basket with VCYTScreener

Data is 15-minute delayed, for informational purposes only. Not investment advice. Prices via Massive.com consolidated feed. Fundamentals via FinancialModelingPrep. News via Finnhub.

VCYT Veracyte, Inc. Stock — $46.44 -3.44% · AlgoThesis